Emergent Biosolutions
EBS
EBS
358 hedge funds and large institutions have $4.45B invested in Emergent Biosolutions in 2020 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 110 increasing their positions, 138 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
4.19% less ownership
Funds ownership: 85.84% → 81.65% (-4.2%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
20% less repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 138
Holders
358
Holding in Top 10
6
Calls
$11.4M
Puts
$7.26M
Top Buyers
| 1 | +$64.8M | |
| 2 | +$35.3M | |
| 3 | +$28.7M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.4M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$19.8M |
Top Sellers
| 1 | -$182M | |
| 2 | -$37.3M | |
| 3 | -$35.2M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$34.2M |
| 5 |
SCM
Snyder Capital Management
San Francisco,
California
|
-$23.4M |